Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Catherine Vézina et al.|The Lancet Oncology|2019Cited by 341
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trialNavin Pinto, Julie R. Park, Steven G. DuBois et al.|Pediatric Blood & Cancer|2018Cited by 39